In short
This article discusses the use of N-Methyl-2-(4'-Methylaminophenyl)-6-Hydroxybenzothiazole, also known as PiB or Pittsburgh compound B, in clinical trials for early-onset Alzheimer's disease caused by genetic mutations. The drug is being studied as part of a larger trial investigating potential disease-modifying therapies for dominantly inherited Alzheimer's disease (DIAD). The research aims to assess the safety, tolerability, and effectiveness of PiB in slowing cognitive decline and improving disease-related biomarkers in individuals at risk for or affected by DIAD.
At a glance
- Drug Name
- N-Methyl-2-(4'-Methylaminophenyl)-6-Hydroxybenzothiazole (PiB)
- Trial Phase
- Phase II/III
- Condition Studied
- Dominantly Inherited Alzheimer's Disease (DIAD)
- Main Objective
- Assess safety, tolerability, and efficacy in slowing cognitive decline and improving biomarkers
- Administration
- Intravenous injection, max 18 mCi daily, 90 mCi total
- Study Duration
- Up to 208 weeks
- Key Measurements
- Cognitive function, clinical assessments, brain imaging, biomarkers in CSF and blood
- Eligibility
- Individuals with or at risk for DIAD-causing mutations, within specific age ranges
What is PiB?
PiB, short for Pittsburgh compound B, is a medical substance with the scientific name N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE. It's also known by other names such as 6-OH-BTA-1 and 2-[4-(Methylamino)phenyl]-1,3-benzothiazol-6-ol. This compound is not a treatment for Alzheimer's disease, but rather a powerful tool used in research to help understand and diagnose the condition.
Use in Alzheimer's Research
PiB is primarily used in a type of brain imaging called PET (Positron Emission Tomography) scanning. In Alzheimer's research, PiB-PET scans are used to visualize and measure the amount of amyloid plaques in the brain. Amyloid plaques are abnormal clusters of protein fragments that build up between nerve cells and are a hallmark of Alzheimer's disease.
By using PiB in PET scans, researchers can:
- Detect the presence of amyloid plaques in the brain
- Monitor changes in amyloid levels over time
- Assess the effectiveness of potential Alzheimer's treatments in reducing amyloid buildup
Clinical Trial Information
PiB is being used in a significant clinical trial for Alzheimer's disease. This trial, known as the "Dominantly Inherited Alzheimer Network Trial" (DIAN-TU), is studying potential treatments for a rare form of Alzheimer's disease called Dominantly Inherited Alzheimer Disease (DIAD).
Key points about this trial include:
- It's a Phase II/III trial, which means it's testing both the effectiveness and safety of potential treatments
- The trial is focusing on people who have a genetic mutation that causes early-onset Alzheimer's disease
- Participants include both those who already have symptoms and those who are at risk but don't yet have symptoms
- The study uses PiB-PET scans as one of its primary ways to measure the effectiveness of treatments
How PiB is Administered
In the clinical trial, PiB is administered as an injection. Specifically, it's given through an intravenous bolus, which means it's injected directly into a vein in a single, rapid dose. This allows the PiB to quickly circulate through the body and reach the brain, where it can bind to amyloid plaques for imaging.
Safety and Dosage
The safety of PiB is carefully monitored in clinical trials. Here are some important points about its use:
- The maximum daily dose is 18 millicuries (mCi). A millicurie is a unit used to measure radioactivity.
- The maximum total dose over the course of the study is 90 mCi.
- The treatment period can last up to 208 weeks (about 4 years).
It's important to note that PiB is used in very small amounts for imaging purposes and is not a treatment itself. The radiation exposure from PiB-PET scans is carefully controlled and monitored to ensure participant safety.
Importance in Dominantly Inherited Alzheimer's Disease
PiB plays a crucial role in studying Dominantly Inherited Alzheimer's Disease (DIAD). This rare form of Alzheimer's is caused by specific genetic mutations and often leads to early-onset dementia, sometimes affecting people in their 30s or 40s.
By using PiB-PET scans, researchers can:
- Detect amyloid buildup in the brain before symptoms appear
- Track how quickly amyloid accumulates over time
- Assess whether potential treatments can slow down or stop amyloid buildup
- Compare amyloid levels between those who carry the genetic mutation and those who don't
This information is invaluable for understanding how Alzheimer's disease progresses and for developing and testing new treatments that could potentially prevent or slow down the disease.